Q-linea: ASTar is about to secure a 3-year US reimbursement at USD 97.50 - Redeye

CMS’ NTAP recommendation is positive, and we can expect a final decision by August, followed by a good chance that the NTAP reimbursement will be effective as of October 2024. The NTAP recommendation is also good timing ahead of the US ASM conference as it allows Q-linea to engage with potential US commercial partners.

Länk till analysen i sin helhet: https://www.redeye.se/research/1015636/q-linea-astar-is-about-to-secure-a-3-year-us-reimbursement-at-usd-97-50?utm_source=finwire&utm_medium=RSS